Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus
Conclusions:
Nalbuphine HCl ER tablets can be safely administered to HD patients without dose adjustment up to 240 mg BID and may hold promise in treating uremic pruritus.
Source: BMC Nephrology - Category: Urology & Nephrology Authors: Amale HawiHarry AlcornJolene BergCarey HinesHoward HaitThomas Sciascia Source Type: research